Business Context and Reporting Period
This Form 6-K filing by Bionomics Limited (not Neuphoria Therapeutics Inc.) covers the period of July 2023, with a specific report date of July 28, 2023. The filing updates shareholders regarding the ongoing process of de-listing from the Australian Securities Exchange (ASX).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a procedural update regarding corporate governance and exchange status rather than a financial performance report.
Material Changes
The primary material change disclosed is the progression of the ASX de-listing process. The company has issued a Shareholder Communication Announcement and a Shareholder Communication Letter to inform investors of this status.
Guidance, Outlook, and Risks
Management commentary is limited to the procedural update on the de-listing. No financial guidance, future outlook, or specific risk factors beyond the de-listing process are detailed in this specific filing text. An ADS Conversion Facility Election Form is noted as available on the company's website.
Investor Verification Checklist
- Verify the current status of the ASX de-listing process via the attached Shareholder Communication Letter (Exhibit 99.2).
- Confirm the availability and terms of the ADS Conversion Facility Election Form on the company website.
- Review the Shareholder Communication Announcement (Exhibit 99.1) for specific timelines and instructions for shareholders.
- Note that this filing contains no financial performance data; refer to the most recent Form 20-F for financial metrics.